No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

Get Instant Summarized Text (Gist) Microdosing LSD for ADHD shows no significant advantage over a placebo in symptom improvement, according to a randomized clinical trial. Conducted over six weeks ...

AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata THURSDAY, March 13, 2025 (HealthDay News) — For adults with severe alopecia areata, ivarmacitinib, a selective Janus ...

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study ...

The response rate difference versus placebo was 25.6% and 31.6%, respectively, for ivarmacitinib 4 mg and 8 mg, with no reported deaths, thromboembolic events, or major cardiovascular events.

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

THURSDAY, March 13, 2025 (HealthDay News) — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable ...

The researchers found that 34.9, 40.6, and 9.0 percent of those assigned to ivarmacitinib 4 mg, 8 mg, and placebo, ...

Get Instant Summarized Text (Gist) Ivarmacitinib, a selective JAK1 inhibitor, is effective and tolerable for adults with severe alopecia areata at doses of 4 mg and 8 mg. In a phase 3 trial, 34.9% ...